Free Biopharma Stock Content

$XBI $89.86 | -2.55% Covid Updates $MRNA -4.3% Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 ...

$XBI $92.21 | +3.58% Covid Updates $NVAX +6.7% Novavax and Serum Institute of India Announce First Emergency Use Authorization of...

$XBI $89.02 | -3.41% Covid Updates $MRNA -2.0% Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven...

As we reach the middle of March, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves...

$XBI $92.16 | +2.9% Covid Updates $MRNA +6.3% MODERNA SUBMITS AMENDMENT TO THE EMERGENCY USE AUTHORIZATION FOR AN ADDITIONAL BOOSTER...

$XBI $89.56| +3.91% Covid Updates $MRNA -0.5% Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years) source $EIGR...

$XBI $86.19 | +4.79% Covid Updates $ Pipeline Updates $AZN +1.0% Lynparza reduced risk of death by 32% in the adjuvant treatment of...

$XBI $82.26 | +1.47% Covid Updates $PFE 0.0% Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster...

$XBI $81.07 | -4.18% Covid Updates $ADMP -6.1% Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the...

(Originally posted 3/11/22) (Updated 3/13/22) 2022 has been a challenging year thus far for biotech investors with XBI down 27% YTD and...

As we enter March, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD...

$XBI $84.53 | -3.9% Pipeline Updates $HARP -27.4% Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and...

$XBI $87.98 | -0.5% Covid Updates $MRNA -2.1% Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent...

BULL THESIS GTHX overall corporate and summary Commercial-stage cancer biopharma company focused on the development and commercialization...

BULL THESIS MDGL overall corporate and executive summary Pursuing novel therapeutics that target a specific thyroid hormone pathway in...

$XBI $88.44 | +4.89% Covid Updates $ Pipeline Updates $NTLA +3.7% Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for...

$XBI $84.32 | +0.67% Covid Updates Pipeline Updates $AFMD +1.5% Affimed Announces Clinical Updates at the Annual Meeting of the American...

$XBI $83.76 | -0.17% Covid Updates Pipeline Updates $LVTX +1.4% LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO...

BULL THESIS HGEN overall corporate and executive summary Multiple upcoming Phase 3 trials for 2022 Lenzi appears to be an active and safe...

As we have reached the end of February, we review moves from smid-cap biopharma companies during this past week as well as for the month...